''Shen-Gu granule'' for the prevention and treatment of glucocorticoid-induced osteoporosis.
Phase 4
Not yet recruiting
- Conditions
- Prevention and treatment of glucocorticoid-induced osteoporosis
- Registration Number
- ITMCTR2000003181
- Lead Sponsor
- Shanghai Tongji Hospital, Tongji University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with a recent history of GC or a recent plan to take glucocorticoids.
Exclusion Criteria
(1) patients with tumor, bone tuberculosis, fracture and other osteoporosis lesions or injuries;
(2) pregnant or lactating women;
(3) allergic constitution or allergic to the known ingredients of the drug;
(4) patients with heart, lung, liver, kidney, hematopoietic system, immune system and other serious diseases.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Shen-Gu granule's efficacy in preventing glucocorticoid-induced osteoporosis?
How does Shen-Gu granule compare to bisphosphonates in managing bone density loss from corticosteroid therapy?
Are there specific biomarkers that identify patients most likely to benefit from Shen-Gu granule for osteoporosis prevention?
What adverse events have been associated with Shen-Gu granule in previous studies and how are they managed?
What are the potential synergies of Shen-Gu granule with other osteoporosis treatments like denosumab or teriparatide?